Rosacea and the Microbiome: A Systematic Review.
IBD
Immune dysregulation
Inflammation
Microbiome
Rosacea
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
23
09
2020
pubmed:
11
11
2020
medline:
11
11
2020
entrez:
10
11
2020
Statut:
ppublish
Résumé
Rosacea, a chronic inflammatory skin disease characterized by recurrent episodes of facial flushing, erythema, pustules, and telangiectasia, largely affects fair-skinned women over 30 years of age. Although a long-recognized entity, the exact pathophysiology of this disease is still debated. Current theories highlight the role of the cutaneous microbiome and its associated inflammatory effects in rosacea's pathogenesis. However, microbiological reverberations are not limited to the skin, as recent studies have described the potential cutaneous effects of alterations in the gastrointestinal (GI) microbiome. Associations with additional GI pathologies, including small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD), have been investigated, as well as Helicobacter pylori infection. In an attempt to better understand and characterize these relationships, as well as current treatment options, we conducted a systematic review of the literature in PubMed, Cochrane, and Embase from their inception to August 6, 2020. We have synthesized the literature findings within three sections of this manuscript: the cutaneous microbiome, the gut microbiome, and therapeutic strategies. Future studies should focus on specific mechanisms linking GI pathology with rosacea manifestations and the role of enteral drugs in mitigating cutaneous symptoms.
Identifiants
pubmed: 33170492
doi: 10.1007/s13555-020-00460-1
pii: 10.1007/s13555-020-00460-1
pmc: PMC7859152
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1-12Références
Holmes AD, Spoendlin J, Chien AL, Baldwin H, Chang ALS. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018;78(1):156–66.
doi: 10.1016/j.jaad.2017.07.055
Weiss E, Katta R. Diet and rosacea: the role of dietary change in the management of rosacea. Dermatol Pract Concept. 2017;7(4):31–7.
doi: 10.5826/dpc.0704a08
Wong F, Rayner-Hartley E, Byrne MF. Extraintestinal manifestations of Helicobacter pylori: a concise review. World J Gastroenterol. 2014;20(34):11950–61.
doi: 10.3748/wjg.v20.i34.11950
Holmes AD. Potential role of microorganisms in the pathogenesis of rosacea. J Am Acad Dermatol. 2013;69(6):1025–32.
doi: 10.1016/j.jaad.2013.08.006
Rastogi V, Singh D, Mazza JJ, Parajuli D, Yale SH. Flushing disorders associated with gastrointestinal symptoms: part 1, neuroendocrine tumors, mast cell disorders and hyperbasophila. Clin Med Res. 2018;16(1–2):16–28.
doi: 10.3121/cmr.2017.1379a
Weinstock L. Crohn’s disease and rosacea: effect of rifaximin and adalimumab. Am J Gastroenterol. 2011;106:S449.
doi: 10.14309/00000434-201110002-01195
Two AM, Wu W, Gallo RL, Hata TR. Rosacea: part I. Introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72(5):749–58 (quiz 759–760).
doi: 10.1016/j.jaad.2014.08.028
O’Reilly N, Menezes N, Kavanagh K. Positive correlation between serum immunoreactivity to Demodex-associated Bacillus proteins and erythematotelangiectatic rosacea. Br J Dermatol. 2012;167(5):1032–6.
doi: 10.1111/j.1365-2133.2012.11114.x
Kendall SN. Remission of rosacea induced by reduction of gut transit time. Clin Exp Dermatol. 2004;29(3):297–9.
doi: 10.1111/j.1365-2230.2004.01461.x
Wang R, Farhat M, Na J, Li R, Wu Y. Bacterial and fungal microbiome characterization in patients with rosacea and healthy controls. Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19315 .
Kim M, Choi KH, Hwang SW, Lee YB, Park HJ, Bae JM. Inflammatory bowel disease is associated with an increased risk of inflammatory skin diseases: a population-based cross-sectional study. J Am Acad Dermatol. 2017;76(1):40–8.
doi: 10.1016/j.jaad.2016.08.022
Casas C, Paul C, Lahfa M, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21(12):906–10.
doi: 10.1111/exd.12030
Searle T, Ali FR, Carolides S, Al-Niaimi F. Rosacea and the gastrointestinal system. Australas J Dermatol. 2020. https://doi.org/10.1111/ajd.13401 .
O’Reilly N, Bergin D, Reeves EP, McElvaney NG, Kavanagh K. Demodex-associated bacterial proteins induce neutrophil activation. Br J Dermatol. 2012;166(4):753–60.
doi: 10.1111/j.1365-2133.2011.10746.x
Whitfeld M, Gunasingam N, Leow LJ, Shirato K, Preda V. Staphylococcus epidermidis: a possible role in the pustules of rosacea. J Am Acad Dermatol. 2011;64(1):49–52.
doi: 10.1016/j.jaad.2009.12.036
Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol. 2015;73(4):604–8.
Egeberg A, Weinstock LB, Thyssen EP, Gislason GH, Thyssen JP. Rosacea and gastrointestinal disorders: a population-based cohort study. Br J Dermatol. 2017;176(1):100–6.
doi: 10.1111/bjd.14930
Nam JH, Yun Y, Kim HS, et al. Rosacea and its association with enteral microbiota in Korean females. Exp Dermatol. 2018;27(1):37–42.
doi: 10.1111/exd.13398
Wedi B, Kapp A. Helicobacter pylori infection in skin diseases: a critical appraisal. Am J Clin Dermatol. 2002;3(4):273–82.
doi: 10.2165/00128071-200203040-00005
Utas S, Ozbakir O, Turasan A, Utas C. Helicobacter pylori eradication treatment reduces the severity of rosacea. J Am Acad Dermatol. 1999;40(3):433–5.
doi: 10.1016/S0190-9622(99)70493-7
Bamford JT, Tilden RL, Blankush JL, Gangeness DE. Effect of treatment of Helicobacter pylori infection on rosacea. Arch Dermatol. 1999;135(6):659–63.
doi: 10.1001/archderm.135.6.659
Herr H, You CH. Relationship between Helicobacter pylori and rosacea: it may be a myth. J Korean Med Sci. 2000;15(5):551–4.
doi: 10.3346/jkms.2000.15.5.551
Chen WX, Ren LH, Shi RH. Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol. 2014;20(42):15657–63.
doi: 10.3748/wjg.v20.i42.15657
Szántó M, Dózsa A, Antal D, Szabó K, Kemény L, Bai P. Targeting the gut-skin axis—probiotics as new tools for skin disorder management? Exp Dermatol. 2019;28(11):1210–8.
doi: 10.1111/exd.14016
Vera N, Patel NU, Seminario-Vidal L. Rosacea comorbidities. Dermatol Clin. 2018;36(2):115–22.
doi: 10.1016/j.det.2017.11.006
Spoendlin J, Karatas G, Furlano RI, Jick SS, Meier CR. Rosacea in patients with ulcerative colitis and Crohn’s disease: a population-based case-control study. Inflamm Bowel Dis. 2016;22(3):680–7.
doi: 10.1097/MIB.0000000000000644
Haber R, El Gemayel M. Comorbidities in rosacea: a systematic review and update. J Am Acad Dermatol. 2018;78(4):786-792.e788.
doi: 10.1016/j.jaad.2017.09.016
Li WQ, Cho E, Khalili H, Wu S, Chan AT, Qureshi AA. Rosacea, use of tetracycline, and risk of incident inflammatory bowel disease in women. Clin Gastroenterol Hepatol. 2016;14(2):220–225.e221–3.
Wu CY, Chang YT, Juan CK, et al. Risk of inflammatory bowel disease in patients with rosacea: results from a nationwide cohort study in Taiwan. J Am Acad Dermatol. 2017;76(5):911–7.
doi: 10.1016/j.jaad.2016.11.065
Goyette P, Boucher G, Mallon D, et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1*01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015;47(2):172–9.
doi: 10.1038/ng.3176
Chang ALS, Raber I, Xu J, et al. Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol. 2015;135(6):1548–55.
doi: 10.1038/jid.2015.53
Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012;24(2):126–35.
doi: 10.5021/ad.2012.24.2.126
Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;6(7):759–64.
doi: 10.1016/j.cgh.2008.02.054
van Zuuren EJ. Rosacea. N Engl J Med. 2017;377(18):1754–64.
doi: 10.1056/NEJMcp1506630
Logger JGM, Olydam JI, Driessen RJB. Use of beta-blockers for rosacea-associated facial erythema and flushing: a systematic review and update on proposed mode of action. J Am Acad Dermatol. 2020;83(4):1088–97.
doi: 10.1016/j.jaad.2020.04.129
Margalit A, Kowalczyk MJ, Żaba R, Kavanagh K. The role of altered cutaneous immune responses in the induction and persistence of rosacea. J Dermatol Sci. 2016;82(1):3–8.
doi: 10.1016/j.jdermsci.2015.12.006
Park JM, Mun JH, Song M, et al. Propranolol, doxycycline and combination therapy for the treatment of rosacea. J Dermatol. 2015;42(1):64–9.
doi: 10.1111/1346-8138.12687
Manzhalii E, Hornuss D, Stremmel W. Intestinal-borne dermatoses significantly improved by oral application of Escherichia coli Nissle 1917. World J Gastroenterol. 2016;22(23):5415–21.
doi: 10.3748/wjg.v22.i23.5415
Fortuna MC, Garelli V, Pranteda G, et al. A case of scalp rosacea treated with low dose doxycycline and probiotic therapy and literature review on therapeutic options. Dermatol Ther. 2016;29(4):249–51.
doi: 10.1111/dth.12355
Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499–12 (quiz 513–494).
Efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea. https://ClinicalTrials.gov/show/NCT04419259 . Accessed 12 Sept 2020.
Timolol for the treatment of acne and rosacea. https://ClinicalTrials.gov/show/NCT02774590 . Accessed 12 Sept 2020.
Safety and efficacy of rifaximin in patients with papulopustular rosacea and positive lactulose breath test. https://ClinicalTrials.gov/show/NCT03864978 . Accessed 12 Sept 2020.
Pulsed dye laser treatment and oxymetazoline hydrochloride (HCl) 1% cream for erythematotelangiectatic rosacea. https://ClinicalTrials.gov/show/NCT04153188 . Accessed 12 Sept 2020.